
Asia Pacific Tumor Ablation Market Report and Forecast 2024-2032
Description
Asia Pacific Tumor Ablation Market Report and Forecast 2024-2032
Asia Pacific Tumor Ablation Market Report and Forecast 2024-2032
Asia Pacific Tumor Ablation Market Outlook
The global tumor ablation market size was valued at USD 1.9 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the increasing incidence of cancer and the rising preference for minimally invasive procedures. It is expected to grow at a CAGR of 16.30% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.
Key Takeaways
- In November 2023 , IceCure Medical Ltd. received approval from the Central Drugs Standard Control Organization (CDSCO) in India for its minimally invasive cryoablation technology ProSense® System based on the updated regulatory requirements. The rising introduction of such innovative treatment options in healthcare settings is likely to elevate the Asia Pacific tumor ablation market value.
- Around 50% of new cancer cases occur in the Asia Pacific every year. Cancer related mortality is projected to rise by 36% by 2030. The rising burden of cancer and associated mortality is expected to directly impact the market demand.
- One of the major market trends is the rising preference for minimally invasive techniques among patients due to benefits like shorter recovery times, reduced pain, and lower risks of complications.
Tumor ablation is a minimally invasive technique that is used to directly target and destroy cancerous cells by employing various energy sources. It is generally utilized for tumors in organs such as liver, kidney, lung, and prostate, and acts as a promising alternative when surgery is not a feasible option. The rising technological advancements that enhance the accuracy, effectiveness, and safety of tumor ablation procedures significantly contribute to the Asia Pacific tumor ablation market growth.
In Asia Pacific, the burden of cancer and associated mortality are increasing at a steady rate, which directly impacts the market demand. Around 50% of new cancer cases occur in the Asia Pacific every year, with the mortality caused by cancer projected to rise by 36% by 2030. This growing incidence of cancer is expected to fuel the need for effective treatment solutions such as tumor ablation, thereby boosting market share.
The presence of a favorable regulatory environment, which encourages the adoption of advanced medical technologies as well as ensures patient safety and efficacy of tumor ablation procedures is expected to augment the Asia Pacific tumor ablation market share. In November 2023, IceCure Medical Ltd. received approval from the Central Drugs Standard Control Organization (CDSCO) in India for its minimally invasive cryoablation technology ProSense® System based on the updated regulatory requirements. The cryoablation therapy treats tumors (benign and cancerous) by freezing and the first breast cancer cryoablation procedure was conducted in June 2023 in India. The rising introduction of such innovative tumor ablation technology in healthcare settings is likely to elevate the market value in the region.
One of the major Asia Pacific tumor ablation market trends is the growing preference for minimally invasive techniques among patients due to benefits like shorter recovery times, reduced pain, and lower risks of complications. This shift towards the growing adoption of tumor ablation techniques is also supported by continuous innovation in medical technology including better imaging techniques and advanced ablation tools, which results in effective treatment and reduced hospital stays. Moreover, the rising government support and increasing healthcare expenditure in the region are anticipated to propel the market growth in the forecast period.
Asia Pacific Tumor Ablation Market Segmentation
Market Breakup by Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- Other Ablation Technologies
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Bone Cancer
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
- Hospitals
- Cancer Specialty Clinics
- Others
- Japan
- India
- ASEAN
- Australia
- Others
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- EDAP TMS
- Medtronic plc
- Boston Scientific Corporation
- AngioDynamics, Inc.
- Merit Medical Systems, Inc.
- Abbott
- Hologic, Inc.
- HealthTronics, Inc.
- SonaCare Medical
- IceCure Medical Ltd.
- Monteris Medical Inc.
FAQs
- What is the Asia Pacific tumor ablation market forecast outlook for 2024-2032?
- What are the major factors aiding the Asia Pacific tumor ablation market demand?
- What are the major Asia Pacific tumor ablation trends?
- What is the market segmentation based on the technology?
- What is the market breakup by mode of treatment?
- What are the major end users of the market?
- What are the applications of the market?
- What is the market segmentation by countries?
- Who are the key players involved in the Asia Pacific tumor ablation market?
Meta description
Asia Pacific tumor ablation market is poised for growth, driven by the expansion of the global market, which was valued at USD 1.9 billion in 2023 and is projected to grow at a CAGR of 14.2% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Asia Pacific Tumor Ablation Market Overview
- 3.1 Asia Pacific Tumor Ablation Market Historical Value (2017-2023)
- 3.2 Asia Pacific Tumor Ablation Market Forecast Value (2024-2032)
- 4 Asia Pacific Tumor Ablation Market Landscape*
- 4.1 Asia Pacific Tumor Ablation: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Asia Pacific Tumor Ablation: Product Landscape
- 4.2.1 Analysis by Technology
- 4.2.2 Analysis by Application
- 5 Asia Pacific Tumor Ablation Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Asia Pacific Tumor Ablation Market Segmentation (2017-2032)
- 6.1 Asia Pacific Tumor Ablation Market (2017-2032) by Technology
- 6.1.1 Market Overview
- 6.1.2 Radiofrequency Ablation
- 6.1.3 Microwave Ablation
- 6.1.4 Cryoablation
- 6.1.5 Irreversible Electroporation Ablation
- 6.1.6 Other Ablation Technologies
- 6.2 Asia Pacific Tumor Ablation Market (2017-2032) by Application
- 6.2.1 Market Overview
- 6.2.2 Kidney Cancer
- 6.2.3 Liver Cancer
- 6.2.4 Breast Cancer
- 6.2.5 Lung Cancer
- 6.2.6 Prostate Cancer
- 6.2.7 Bone Cancer
- 6.3 Asia Pacific Tumor Ablation Market (2017-2032) by Mode of Treatment
- 6.3.1 Market Overview
- 6.3.2 Surgical Ablation
- 6.3.3 Laparoscopic Ablation
- 6.3.4 Percutaneous Ablation
- 6.4 Asia Pacific Tumor Ablation Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals
- 6.4.3 Cancer Specialty Clinics
- 6.4.4 Others
- 6.5 Asia Pacific Tumor Ablation Market (2017-2032) by Country
- 6.5.1 Market Overview
- 6.5.2 Japan
- 6.5.3 India
- 6.5.4 ASEAN
- 6.5.5 Australia
- 6.5.6 Others
- 7 Japan Tumor Ablation Market (2017-2032)
- 7.1 Japan Tumor Ablation Market (2017-2032) by Technology
- 7.1.1 Market Overview
- 7.1.2 Radiofrequency Ablation
- 7.1.3 Microwave Ablation
- 7.1.4 Cryoablation
- 7.1.5 Irreversible Electroporation Ablation
- 7.1.6 Other Ablation Technologies
- 7.2 Japan Tumor Ablation Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Kidney Cancer
- 7.2.3 Liver Cancer
- 7.2.4 Breast Cancer
- 7.2.5 Lung Cancer
- 7.2.6 Prostate Cancer
- 7.2.7 Bone Cancer
- 7.3 Japan Tumor Ablation Market (2017-2032) by Mode of Treatment
- 7.3.1 Market Overview
- 7.3.2 Surgical Ablation
- 7.3.3 Laparoscopic Ablation
- 7.3.4 Percutaneous Ablation
- 7.4 Japan Tumor Ablation Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Hospitals
- 7.4.3 Cancer Specialty Clinics
- 7.4.4 Others
- 8 India Tumor Ablation Market (2017-2032)
- 8.1 India Tumor Ablation Market (2017-2032) by Technology
- 8.1.1 Market Overview
- 8.1.2 Radiofrequency Ablation
- 8.1.3 Microwave Ablation
- 8.1.4 Cryoablation
- 8.1.5 Irreversible Electroporation Ablation
- 8.1.6 Other Ablation Technologies
- 8.2 India Tumor Ablation Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Kidney Cancer
- 8.2.3 Liver Cancer
- 8.2.4 Breast Cancer
- 8.2.5 Lung Cancer
- 8.2.6 Prostate Cancer
- 8.2.7 Bone Cancer
- 8.3 India Tumor Ablation Market (2017-2032) by Mode of Treatment
- 8.3.1 Market Overview
- 8.3.2 Surgical Ablation
- 8.3.3 Laparoscopic Ablation
- 8.3.4 Percutaneous Ablation
- 8.4 India Tumor Ablation Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospitals
- 8.4.3 Cancer Specialty Clinics
- 8.4.4 Others
- 9 ASEAN Tumor Ablation Market (2017-2032)
- 9.1 ASEAN Tumor Ablation Market (2017-2032) by Technology
- 9.1.1 Market Overview
- 9.1.2 Radiofrequency Ablation
- 9.1.3 Microwave Ablation
- 9.1.4 Cryoablation
- 9.1.5 Irreversible Electroporation Ablation
- 9.1.6 Other Ablation Technologies
- 9.2 ASEAN Tumor Ablation Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Kidney Cancer
- 9.2.3 Liver Cancer
- 9.2.4 Breast Cancer
- 9.2.5 Lung Cancer
- 9.2.6 Prostate Cancer
- 9.2.7 Bone Cancer
- 9.3 ASEAN Tumor Ablation Market (2017-2032) by Mode of Treatment
- 9.3.1 Market Overview
- 9.3.2 Surgical Ablation
- 9.3.3 Laparoscopic Ablation
- 9.3.4 Percutaneous Ablation
- 9.4 ASEAN Tumor Ablation Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Hospitals
- 9.4.3 Cancer Specialty Clinics
- 9.4.4 Others
- 10 Australia Tumor Ablation Market (2017-2032)
- 10.1 Australia Tumor Ablation Market (2017-2032) by Technology
- 10.1.1 Market Overview
- 10.1.2 Radiofrequency Ablation
- 10.1.3 Microwave Ablation
- 10.1.4 Cryoablation
- 10.1.5 Irreversible Electroporation Ablation
- 10.1.6 Other Ablation Technologies
- 10.2 Australia Tumor Ablation Market (2017-2032) by Application
- 10.2.1 Market Overview
- 10.2.2 Kidney Cancer
- 10.2.3 Liver Cancer
- 10.2.4 Breast Cancer
- 10.2.5 Lung Cancer
- 10.2.6 Prostate Cancer
- 10.2.7 Bone Cancer
- 10.3 Australia Tumor Ablation Market (2017-2032) by Mode of Treatment
- 10.3.1 Market Overview
- 10.3.2 Surgical Ablation
- 10.3.3 Laparoscopic Ablation
- 10.3.4 Percutaneous Ablation
- 10.4 Australia Tumor Ablation Market (2017-2032) by End User
- 10.4.1 Market Overview
- 10.4.2 Hospitals
- 10.4.3 Cancer Specialty Clinics
- 10.4.4 Others
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication Year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by Year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share by Top 5 Companies
- 16.2 EDAP TMS
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 Medtronic plc
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Boston Scientific Corporation
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 AngioDynamics, Inc.
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Merit Medical Systems, Inc.
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Abbott
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 Hologic, Inc.
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 HealthTronics, Inc.
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 SonaCare Medical
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 IceCure Medical Ltd.
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 16.12 Monteris Medical Inc.
- 16.12.1 Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic Reach and Achievements
- 16.12.4 Mergers and Acquisitions
- 16.12.5 Certifications
- 17 Asia Pacific Tumor Ablation Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.